NeoVolta Announces Strategic U.S. Battery Cell Supply and BESS Manufacturing Collaboration with SK On

Five-Year Agreement Secures 9 GWh of U.S.-Manufactured LFP Cell Supply for NeoVolta Power

Additional 9 GWh Cell Supply and Pack Purchase Arrangement, Under Which SK On Will Purchase Energy Storage Packs from NeoVolta Power From 2027 through 2031, Expanding Total Collaboration to 18 GWh

SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV) (“NeoVolta” or the “Company”), a U.S.-based energy technology company delivering scalable energy storage solutions, today announced that its majority-owned subsidiary, NeoVolta Power, LLC (“NeoVolta Power”), has entered into a five-year strategic supply and manufacturing collaboration with SK On (“SK On”).

The collaboration begins with a signed agreement for SK On to supply 9 gigawatt-hours (“GWh”) of U.S.-manufactured lithium iron phosphate (“LFP”) battery cells to NeoVolta Power from 2027 through 2031. The agreement also establishes a framework for broader collaboration in which SK On will supply an additional 9 GWh of LFP cells to NeoVolta Power from 2027 through 2031, and NeoVolta Power will produce energy storage packs for purchase by SK On. Together, the initial cell-supply agreement and broader pack-manufacturing collaboration are expected to support up to 18 GWh of combined activity between the companies.

Key highlights

Get the latest news


delivered to your inbox

Sign up for The Manila Times newsletters

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

• Long-term U.S. cell supply: The signed five-year agreement provides for 9 GWh of U.S.-manufactured LFP cell supply from SK On from 2027 through 2031, supporting NeoVolta Power’s Pendergrass production expansion.
• Broader pack purchase collaboration: The parties have established a framework under which SK On will provide an additional 9 GWh of LFP cells, NeoVolta Power will produce energy storage packs to be purchased by SK On from 2027 through 2031.
• Strategic manufacturing opportunity: The collaboration establishes SK On as a strategic supply chain partner and customer for NeoVolta Power’s domestic BESS manufacturing platform as demand for reliable, scalable power infrastructure grows across utility, commercial, industrial, AI data-center markets.
• Capacity expansion potential: The scale and multi-year nature of the relationship support NeoVolta Power’s evaluation of additional production capacity at Pendergrass, including a second production line designed around pouch-format LFP cells.
• Domestic supply-chain position: The collaboration advances NeoVolta Power’s strategy to pair U.S.-manufactured LFP cells with domestic BESS manufacturing for commercial, industrial and utility-scale BESS applications.

Strategic Collaboration

“This collaboration represents an important milestone in NeoVolta’s expansion into large-scale energy storage and the continued buildout of our U.S. manufacturing platform,” said Ardes Johnson, Chief Executive Officer of NeoVolta. “The initial agreement secures long-term access to U.S.-manufactured LFP cells for our Pendergrass production expansion, while the broader collaboration positions NeoVolta Power to manufacture energy storage packs for SK On. Together, these initiatives reinforce our strategy to build a domestic energy storage platform designed to meet growing demand for reliable, high-performance BESS solutions.”

The signed agreement establishes SK On as the primary cell supplier for NeoVolta Power’s LFP pouch-cell-based BESS products. The broader collaboration will leverage NeoVolta Power’s domestic manufacturing capabilities, with SK On supplying additional LFP cells for incorporation into battery energy storage packs designed and manufactured by NeoVolta Power and purchased by SK On.

“This partnership strengthens SK On’s position in the U.S. BESS market and brings together SK On’s U.S.-made LFP battery technology with NeoVolta Power’s growing energy storage manufacturing capabilities,” said Daejin Choi, Head of ESS Business at SK On. “We view NeoVolta Power as a strategic partner as we expand our presence in the U.S. energy storage market. By combining our respective capabilities, we will pursue new commercial opportunities and deliver competitive BESS solutions that meet evolving market needs.”

Domestic Manufacturing Platform

NeoVolta Power’s Pendergrass, Georgia facility is designed to manufacture BESS products for commercial, industrial and utility-scale applications. By pairing U.S.-manufactured LFP cells with U.S.-based battery BESS manufacturing, the Company believes its platform is positioned to serve customers seeking reliable and domestic content BESS solutions.

The Company’s initial Pendergrass production line remains on track to advance through commissioning and production-ramp activities. The multi-year strategic collaboration with SK On is expected to accelerate NeoVolta Power’s expansion from its initial Pendergrass production line to a two-line manufacturing platform targeting up to 8 GWh of annual BESS production capacity in 2028.

About NeoVolta

NeoVolta is an innovator in energy storage solutions dedicated to advancing reliable, high-performance power infrastructure for residential, commercial, and utility applications. With a focus on scalable technology, domestic manufacturing, and strategic partnerships, NeoVolta is positioned to support the accelerating transition toward resilient energy systems.

For more information, visit www.neovolta.com.

About SK On

SK On is a global leading battery & trading company committed to technological innovation for a better, sustainable future.

SK On aims to accelerate the green energy transition by leveraging its global production base and R&D capabilities, as well as its manufacturing and quality management know-how.

Headquartered in Seoul, South Korea, SK On has a worldwide presence with battery plants currently operating or in construction across the United States, Europe, and Asia.

For more information, visit: http://eng.sk-on.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, among other things, statements regarding anticipated battery-cell supply, future battery-pack purchases, the implementation of future order documents, production and delivery schedules, future manufacturing capacity, the potential establishment and timing of additional production lines, domestic-content and supply-chain characteristics, the availability or applicability of tax incentives and credits, customer demand, market opportunities, and the anticipated benefits and future opportunities associated with the relationship between NeoVolta Power and SK On.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, risks related to the parties’ ability to finalize and implement future order documents and commercial terms; satisfy technical and product-specification requirements; execute production ramps; obtain financing; source materials; meet regulatory or tax-credit requirements; respond to changes in tariffs or raw-material prices; and other risks described in NeoVolta’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. NeoVolta undertakes no obligation to update these statements except as required by law.

Contacts

NEOV Investors

Bryan Baritot

Alliance Advisors IR

[email protected]  

NEOV Media

Email: [email protected]

Source link

US PV manufacturing: how much capacity will actually be online by 2030? 

US PV manufacturing: how much capacity will actually be online by 2030?  – PV Tech

Skip to content

Close

Previous

Next

Source link

Canadian Solar Q2 Earnings Call Highlights — TradingView News

Canadian Solar CSIQ reported second-quarter 2026 revenue of $1.2 billion, reaching the high end of its guidance range, as stronger module shipments in the United States and accelerated energy-storage deliveries supported manufacturing performance. The company recorded a net loss attributable to shareholders of $77 million, or $1.40 per share, amid elevated freight costs and ramp-up expenses at its Jeffersonville, Indiana, solar-cell facility.

CEO Colin Parkin said Canadian Solar recognized revenue on 3.1 gigawatts of solar modules during the quarter and shipped 3.7 gigawatt-hours of energy-storage products, exceeding its storage shipment guidance. The company recognized revenue on 3.3 gigawatt-hours of storage solutions.

Gross margin was 13.9%, in line with management’s outlook. Parkin said profitability was affected by higher freight expenses tied to geopolitical uncertainty, as well as near-term costs associated with bringing the Jeffersonville facility into production. The manufacturing segment recorded an operating loss of $49 million.

U.S. Manufacturing Expansion and Backlog

Canadian Solar said its Jeffersonville plant is the first commercially operational heterojunction, or HJT, solar-cell manufacturing facility in the United States. Phase 1 of the facility is being ramped to 2.1 gigawatts of capacity and is expected to enter full-scale production on Oct. 1.

The company plans to begin installing equipment for Phase 2 before year-end, with total nameplate cell capacity at Jeffersonville expected to reach 6.3 gigawatts in 2027. Combined with Canadian Solar’s 10-gigawatt module plant in Texas, Parkin said the expansion would establish CSI Solar as one of North America’s largest integrated photovoltaic manufacturers.

Canadian Solar has secured more than 13 gigawatts of contracted backlog for domestically manufactured HJT and TOPCon n-type bifacial modules, with deliveries scheduled through 2029. Management said the backlog has a value exceeding $4.5 billion and includes agreements with U.S. utilities, independent power producers, developers and engineering, procurement and construction providers.

Parkin said nearly half of quarterly module volume was shipped to North America. He also said freight costs should decline as the company expands production in the region, reducing its dependence on overseas shipping. While freight costs are incorporated into contracts, Parkin said domestic manufacturing should reduce logistics costs over time.

Storage Deliveries and Data-Center Demand

Canadian Solar’s e-STORAGE unit delivered energy-storage systems to utility-scale projects in North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. The company said storage results exceeded guidance because deliveries accelerated for two projects in the U.S. and Canada.

At quarter-end, e-STORAGE’s contracted backlog stood at $3.5 billion, including long-term service agreements covering 34 gigawatt-hours of projects. Parkin said demand associated with data centers is moving from discussions toward contracted opportunities.

Earlier in the year, e-STORAGE secured a contract with a major U.S. utility for a 500-megawatt, 2.5-gigawatt-hour direct-current project intended to support data-center grid infrastructure and resilience. Management said battery storage can help data centers address power availability and grid stability by increasing utilization of existing transmission infrastructure and responding to changes in electricity demand.

The company said its storage offering includes internally produced battery cells, the SolBank platform, power-conversion equipment, energy-management controls, engineering and commissioning services, and long-term service agreements.

Recurrent Energy Results and Portfolio Actions

Recurrent Energy, Canadian Solar’s project development business, generated $117 million of second-quarter revenue. CEO Dylan Marx said revenue declined sequentially because several project sales shifted into the second half of the year, though electricity sales increased following the commercial operation of a large solar asset in Spain.

Recurrent Energy reported an operating loss of $19 million, reflecting muted project sales and a $24 million impairment charge associated with an upcoming Latin American project sale.

During the quarter, Recurrent Energy brought a 426-megawatt solar asset in Spain into commercial operation and connected the 150-megawatt Carwarp project in Australia, which is supported by a long-term power purchase agreement with Microsoft. The unit also closed a $695 million construction financing and tax-equity package for its 330-megawatt Cobalt solar project in California. MUFG and NORD/LB provided construction loans, while Wells Fargo provided tax equity.

As of June 30, Recurrent Energy had secured grid interconnections for about 6 gigawatts of solar and 13 gigawatt-hours of storage projects globally, excluding operating projects. Its total development pipeline included nearly 22 gigawatts of solar and 84 gigawatt-hours of storage.

Marx said Recurrent Energy is pruning lower-margin opportunities, including scaling back its Europe, Middle East and Africa pipeline after reviewing permitting, technical and commercial viability. The company expects to selectively monetize operating, construction-stage and development assets in the second half to recycle capital, improve financial flexibility and address leverage.

Balance Sheet, Policy and Outlook

Chief Financial Officer Xinbo Zhu said operating cash flow was negative $181 million in the second quarter, primarily due to working-capital changes. Total assets rose to $16.1 billion, while total debt increased to $7.1 billion, mainly because of non-recourse construction financing for U.S. solar and storage projects under Recurrent Energy.

Capital expenditures were $172 million in the quarter, largely directed toward U.S. manufacturing initiatives. Canadian Solar expects full-year 2026 capital expenditures of approximately $1.3 billion, including spending on Jeffersonville’s second phase, expanded module capacity in Mesquite, Texas, and an energy-storage facility in Southeast Asia. The company ended the quarter with $1.9 billion in cash.

Management also discussed the Trump administration’s Section 232 announcement related to imported polysilicon and derivative products. Parkin said the company views the policy direction as supportive of domestic manufacturing and expects it to strengthen U.S. solar pricing. Thomas Koerner, Corporate Senior Vice President, said the stated value of the company’s 13-gigawatt domestic-module backlog does not yet include potential Section 232-related adjustments.

For the third quarter, Canadian Solar expects to recognize revenue from 3.5 gigawatts to 3.8 gigawatts of module shipments and deliver 3.4 gigawatt-hours to 3.8 gigawatt-hours of energy storage. Revenue is projected at $1.3 billion to $1.5 billion, with gross margin expected between 13.5% and 15.5%.

The company reiterated full-year U.S. shipment guidance of 6.5 gigawatts to 7 gigawatts of modules and 4.5 gigawatt-hours to 5.5 gigawatt-hours of energy storage. Parkin said Canadian Solar expects U.S. solar and storage volumes to increase sequentially in each remaining quarter of 2026.

About Canadian Solar CSIQ

Canadian Solar Inc CSIQ is a global renewable energy company that specializes in the design, development and manufacturing of solar photovoltaic (PV) modules and system solutions. Founded in 2001 and headquartered in Guelph, Ontario, the company has grown to become one of the world’s largest solar module suppliers. Canadian Solar offers a comprehensive portfolio of products, including mono- and multi-crystalline solar cells and modules, as well as advanced energy storage and system integration solutions tailored for residential, commercial and utility-scale applications.

In addition to manufacturing solar components, Canadian Solar provides end-to-end services encompassing project development, engineering, procurement and construction (EPC), as well as operations and maintenance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Source link

Manufacturers Take Unlawful EPA Air Standard Fight to Supreme Court

New NAM Analysis Finds Rule Threatens Nearly $1 Trillion in Manufacturing Investment and More Than 122,000 American Jobs

Washington, D.C. – Today, the National Association of Manufacturers joined a coalition of leading business groups in filing a petition for certiorari asking the U.S. Supreme Court to review and reverse the D.C. Circuit’s decision allowing the Environmental Protection Agency’s unlawful and unworkable air quality standard for fine particulate matter, or PM2.5, to stand.

“The Biden administration took an unlawful regulatory shortcut to impose an unworkable air standard that makes it harder to grow manufacturing in America and create well-paying jobs,” said NAM Chief Legal Officer and Corporate Secretary Linda Kelly. “Manufacturers have fought this rule from the beginning because the consequences for investment, growth and American competitiveness are enormous: investment, jobs and America’s ability to compete.

“In 2025, the EPA under the Trump administration agreed, asking the court to vacate the new PM2.5 standard and echoing manufacturers’ concerns that the previous administration had exceeded its authority.

“Yet, the D.C. Circuit allowed the rule to stand, relying on a legal argument the previous administration never invoked to defend its actions. An agency cannot simply disregard the substantive safeguards required by Congress to impose a sweeping new regulatory burden—and a court should not rescue an unlawful rule with an argument the government never raised.

“Manufacturers need the ability to obtain permits, expand operations, modernize facilities and invest in communities across the country. This standard puts those investments and the jobs they support at risk.”

In 2024, the EPA lowered the National Ambient Air Quality Standards for PM2.5 from 12 micrograms per cubic meter to 9. According to new NAM analysis, a standard of 9 threatens at least 474 manufacturing projects announced in the United States since Jan. 1, 2025—representing nearly $1 trillion in investment and more than 122,000 American jobs.

Background:

The Clean Air Act requires the EPA to conduct a thorough review of the NAAQS every five years to determine whether existing standards should be retained or revised. Following a complete review in 2020, the EPA retained the PM2.5 standard of 12 micrograms per cubic meter.

The previous administration subsequently reopened that completed review and in 2024 lowered the standard to 9 micrograms per cubic meter. The NAM and seven leading business groups challenged the rule in the D.C. Circuit, arguing that the EPA lacked authority to revise the standard through an off-cycle reconsideration without conducting the thorough review required by the Clean Air Act.

In November 2025, the EPA reversed the federal government’s position in the litigation and asked the D.C. Circuit to vacate the rule, agreeing with the NAM that the previous administration had used an unlawful regulatory shortcut.

On June 26, 2026, the D.C. Circuit nevertheless upheld the rule, concluding that the EPA could revise the standards outside the five-year review cycle without completing a thorough review. In reaching that conclusion, the court relied on a provision of the Clean Air Act that the previous administration had not invoked in defending the rule.

-NAM-

The National Association of Manufacturers is the largest manufacturing association in the United States, representing small and large manufacturers in every industrial sector and in all 50 states. Manufacturing employs nearly 13 million men and women, contributes $3 trillion to the U.S. economy annually and accounts for nearly 52% of private-sector research and development. The NAM is the powerful voice of the manufacturing community and the leading advocate for a policy agenda that helps manufacturers compete in the global economy and create jobs across the United States. For more information about the NAM or to follow us on Twitter and Facebook, please visit www.nam.org.

Source link

Wind Manufacturing and Supply Chain

The U.S. wind market has a complex supply chain. There are more than 500 U.S. manufacturing facilities specializing in wind components such as blades, towers, and generators, as well as turbine assembly across the country. Since 1999, the average generating capacity of newly installed wind turbines has more than doubled to 3 MW.

Advancements in composite materials, automation, and more efficient manufacturing processes have helped domestic manufacturers dramatically increase productivity throughout the past decade. The wind supply chain that has developed in the United States has increased the domestic content of wind turbines installed in the United States, with over 80% of nacelle assembly and up to 70% of tower manufacturing occurring in the United States for turbines installed here.

As the size and complexity of wind turbines grow, so do the manufacturing process requirements and component transportation costs, which in turn increase the need for local manufacturers who can overcome technical and logistical challenges. The average utility-scale wind turbine contains roughly 8,000 parts, including blades up to 100 meters (over 300 feet) in length and towers around 94 meters (308 feet) high, roughly the height of the Statue of Liberty. New towers are being made even taller to capture stronger winds at higher elevations.

In February 2022, DOE released a series of reports on American manufacturing supply chains, reviewing both the obstacles to a reliable supply of key materials and opportunities for improvement. 

The wind report covers components, processed and raw materials, recycling, digital products, and the wind industry workforce. It discusses U.S. wind industry competitiveness, includes a supply-chain risk assessment, and lists opportunities for private-sector collaboration to address vulnerabilities and enhance competitiveness.

The open-source Renewable Energy Materials Properties Database, released in August 2023, provides a comprehensive compilation of the type, quantity, country of origin, source, significant uses, projected availability, and physical properties of materials used by wind (as well as solar) power technologies. 

Source link

Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity

Celularity’s new manufacturing collaboration with MuseCell Innovations is intended to establish U.S. production for the Dezawa MuseCell platform, with MCI projecting that a broader relationship could generate more than $300 million in aggregate purchases from Celularity over five years.

Key Investor Takeaways

• Celularity (NASDAQ:CELU) will undertake activities to establish U.S. manufacturing of Dezawa MuseCells at its Florham Park, New Jersey facility.

• The collaboration also covers manufacturing of DMC-derived products, including Dezawa MuseExosomes and Dezawa MuseSecretome.

• MuseCell Innovations projects that an expanded relationship could result in more than $300 million of aggregate purchases from Celularity over five years, based on current market conditions and its own platform projections.

• The broader manufacturing collaboration is anticipated to create more than 200 high-tech jobs at Celularity’s New Jersey facility.

• The initial project must be successfully completed before the companies pursue the wider manufacturing relationship, making execution an important near-term consideration.

Why CELU Stock Is in Focus

Celularity (NASDAQ:CELU) and MuseCell Innovations have entered into an additional U.S. manufacturing collaboration aimed at establishing domestic production of MCI-authenticated Dezawa MuseCells at Celularity’s 147,215-square-foot Florham Park facility.

The initial program will establish manufacturing capability for DMC preparations produced from qualified starting materials under the licensed Dezawa Method and MCI product specifications.

Celularity will also support production of products derived from the platform, including Dezawa MuseExosomes and Dezawa MuseSecretome. Each will have dedicated manufacturing processes, analytical characterization, specifications and release criteria.

Following successful completion of the initial project, the companies intend to broaden their manufacturing relationship across additional products and programs.

Why This Matters for Investors

The potential commercial scale is the most significant element for investors. MCI believes the expanded relationship could generate more than $300 million in aggregate purchases from Celularity over five years.

That figure is a projection rather than committed revenue. It is based on current market conditions and MCI’s projections for the Dezawa MuseCell platform, and includes potential future programs extending beyond the initial manufacturing project.

Even so, the collaboration could provide Celularity with an opportunity to increase utilization of manufacturing infrastructure it has already developed. Its New Jersey site includes nine Grade C/ISO 7 and six Grade D/ISO 8 manufacturing suites alongside process development, CMC, analytical and quality capabilities.

The arrangement may therefore broaden the role of Celularity’s infrastructure beyond supporting its proprietary cellular medicine pipeline. Manufacturing third-party technologies could create an additional commercial use for those capabilities while the company continues developing programs including cenplacel-L.

The anticipated creation of more than 200 specialized positions also indicates the scale envisioned for the broader collaboration, although those jobs are tied to the subsequent expanded manufacturing relationship rather than solely to the initial project.

What to Watch Next

Successful establishment of U.S. manufacturing for MCI-authenticated DMC preparations is the first major milestone.

Investors may then watch for formal expansion into additional products and programs and, importantly, evidence that MCI’s projected purchases begin converting into contracted manufacturing activity and revenue for Celularity.

The utilization of the Florham Park facility and progress toward the anticipated expansion of its workforce could provide further indicators of how materially the collaboration is scaling.

Celularity stock price

Source link

Questions Answered on Trade, Tariffs and U.S. Manufacturing

C-SPAN

AAM’s Scott Paul gets into detail live on C-SPAN.

Unless you’ve been living under a rock, you’ve likely noticed that tariffs – a certain president’s favorite word – have been in the news a lot recently. And tariffs can have a significant effect on U.S. manufacturing activity. So, how to analyze manufacturing’s outlook? Alliance for American Manufacturing (AAM) President Scott Paul was on C-SPAN’s Washington Journal program last week, where he tackled that question and others.

You can watch the entire segment here. Or see a couple of clips from the appearance below:

How are America’s factories faring in 2026?

Paul wrote about this recently on AAM’s blog.

“There was a period where manufacturing was having some challenges. I think we’re out of that now,” he said. “You’re seeing some of the results of the factory construction boom. Some of this goes back to the Biden administration, there’s evidence of a lot of factory construction that started in 2022 and 23 with respect to semiconductors, pharmaceuticals, some other goods like that, and has been continuing, although at a slightly lower rate, and now people are coming to fill jobs in those factories.”

AI is Bringing a New Generation of Workers to U.S. Factories

“Young people for a whole generation have been conditioned not to look at manufacturing for a career and there’s strong evidence that is changing, particularly as AI hits those entry-level positions that are white collar and all of a sudden the idea of putting on a tool belt or going to trade school and potentially making 80 or 100,000 dollars as an electrician at a factory looks a lot more appealing,” Paul said.

Manufacturing is a ladder to the Middle class

“I think there has been an imbalance between labor and capital that’s been well documented, that has expanded over the last couple of decades,” Paul said. “I do think manufacturing is an industry where you can still find good wages in the United States and particularly for the majority of Americans who won’t have a four-year degree. It’s a ladder to the middle class.”

China’s currency is crushing U.S. manufacturing

“There have been active efforts over the decades to keep the value of the Chinese currency low in order for them to gain a trade advantage. It makes their goods cheaper to send overseas. I wish the Trump administration did more on currency, particularly with respect to China,” Paul said. “I think that’s necessary to have a better relationship moving forward. Hopefully Trump will raise that with [Chinese leader Xi Jinping] when they meet in September.”

Are Chinese autos coming to the United States?

Don’t let ’em in, we say.

“What the Carney government in Canada has done, I think, is defeating for the Canadian auto industry, and that is to turn to China and to say to some of the Chinese auto companies, ‘come in. We’re going to allow you to import some cars into our market. You can enter into joint ventures with some of our companies,’” Paul said. “And what we’ve seen happen in other places around the world that have tried to accommodate that is that it has completely wiped out the auto industries and the Chinese companies are taking over. That’s happening in real time right now in Europe. It’s happened in the UK. It happened in Australia.”

U.S. national security depends on strategic tariffs

“[National security] is the basis for the tariffs that have been in place since 2018 on steel and aluminum. That was under section 232,” Paul said. “And those have been durable. Biden kept those tariffs on. And when you hear Members of Congress raise concerns about tariffs its generally not those steel and aluminum tariffs, it’s some of the other trade actions the administration has taken. That’s not universally true but I think generally true. I completely agree we have to have a baseline productive capacity for critical metals like steel and aluminum that go into defense purposes.”  

You can find the entire C-SPAN segment here.

Source link

Celularity-MuseCell U.S. Manufacturing Collaboration | CELU Stock News

Key Terms

cGMP-ready

regulatory

Facility, equipment, process, or production plan that is configured and documented to meet current Good Manufacturing Practice (cGMP) regulations used for drugs, biologics, and some medical products. Being cGMP-ready means the company has the controls, procedures, recordkeeping, and physical setup needed to manufacture to regulatory quality standards—like having a kitchen not just clean but inspected, with recipes and logs so every batch is consistent. Investors care because cGMP readiness affects how quickly a product can enter regulated markets and how likely regulators are to accept manufactured product quality.

ISO 7

technical

ISO 7 is a cleanroom classification from the international standard ISO 14644-1 that specifies how many airborne particles of certain sizes may be present in a controlled environment. Think of it as a tightly filtered room with strict airflow and cleaning rules that keeps dust and microbes far below ordinary levels. Investors care because ISO 7 facilities are often required for manufacturing pharmaceuticals, medical devices, and sensitive electronics, and their presence signals production capability and regulatory readiness.

ISO 8

technical

A designation for a cleanroom under the ISO 14644-1 standard indicating the maximum number of airborne particles allowed per cubic meter; ISO 8 permits larger numbers of particles than stricter classes, so it is used for less-stringent controlled environments. Investors care because cleanroom class affects a company’s ability to manufacture or test sensitive products—like drugs, medical devices, or electronics—and signals the level of contamination control in a production facility.

chemistry, manufacturing and controls (CMC)

regulatory

Chemistry, manufacturing and controls (CMC) is the set of scientific and operational steps that show how a drug or biologic is made, what goes into it, and how its quality is consistently checked—think of it as the recipe, the factory process, and the quality checklist for a medicine. Investors care because strong CMC reduces risks around regulatory approval, production delays, batch failures and unexpected costs, directly affecting a product’s ability to reach market and generate revenue.

chain of custody

regulatory

“Chain of custody” is the process of keeping a clear and documented record of how physical or digital evidence is handled, from collection to final use. It ensures that the evidence remains unaltered and trustworthy, much like tracking a package from sender to recipient to confirm it hasn’t been tampered with. This is important for investors because it helps verify the integrity and accuracy of information or assets being evaluated.

See more from StockTitan in Google Search and AI answers.
Adds StockTitan as a preferred source · opens Google

08/27/2026 – 09:00 AM

Collaboration is intended to expand U.S. manufacturing of Dezawa MuseCells® initially across qualified perinatal sources using the licensed Dezawa Method™ and manufacturing of DMC derived products, including Dezawa MuseExosomes® and Dezawa MuseSecretome®

FLORHAM PARK, N.J. & SINGAPORE–(BUSINESS WIRE)–
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and MuseCell Innovations® Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New Jersey facility.

The initial program is designed to establish manufacturing capability for MCI-authenticated DMC preparations. Under the MCI platform, a preparation is authenticated as a DMC product through perinatal, bone marrow or adipose qualified starting material, manufactured under the licensed Dezawa Method and conformance to MCI’s product specifications. In addition to DMC manufacturing, the collaboration encompasses the manufacture of DMC-derived products, including Dezawa MuseExosomes and Dezawa MuseSecretome. Each product will be supported by dedicated manufacturing processes, analytical characterization, specifications and release criteria appropriate to its distinct product profile.

Following successful completion of the initial project, Celularity and MCI intend to build a broader manufacturing relationship across additional products and programs. Based on current market conditions and MCI’s projections for the Dezawa MuseCell platform, MCI believes that the expanded relationship could result in more than $300 million in aggregate purchases from Celularity over the next five years. This estimate reflects the potential scope of future programs beyond the initial project, which the parties would pursue together as the collaboration develops.

“Cellular medicine remains at the center of Celularity’s strategy, including our continued advancement of our proprietary placental-derived technologies,” said Robert J. Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity. “Our collaboration with MCI demonstrates how the manufacturing infrastructure and cellular expertise we have built can also support innovative third-party technologies. We look forward to expanding U.S. manufacturing for the Dezawa MuseCell platform and working with MCI to manufacture additional products derived from the platform.”

“The ability to manufacture advanced cellular technologies reproducibly and at scale is fundamental to the future of medicine,” said Peter H. Diamandis, M.D., Co-Founder and Director of Celularity. “Bob Hariri and Mari Dezawa are both pioneers in cell therapy, and this collaboration brings together their complementary scientific vision and expertise. Celularity has invested in the infrastructure and capabilities required to manufacture sophisticated cellular products, both to advance our own placental-derived technologies and to support innovators such as MCI. This collaboration demonstrates how pioneering science, paired with scalable manufacturing, can accelerate the continued advancement of cellular medicine.”

Celularity operates a 147,215-square-foot, purpose-built facility in Florham Park, New Jersey, which includes a cGMP-ready manufacturing center with nine Grade C/ISO 7 and six Grade D/ISO 8 manufacturing suites designed for commercial production of cellular therapies and advanced biomaterials. Celularity’s integrated capabilities include process development, product specific chemistry, manufacturing and controls (CMC), advanced cell manufacturing, analytical methods and quality systems. The collaboration expands the utilization of Celularity’s manufacturing infrastructure and cellular medicine expertise while Celularity continues to advance its own proprietary cellular medicine programs, including cenplacel-L, its placental derived allogeneic cell therapy. The subsequent broader manufacturing collaboration is anticipated to generate more than 200 high-tech employment opportunities at the Florham Park site during the scope of the expanded collaboration, spanning specialized positions in biomanufacturing, quality control, engineering and support functions.

“By bringing a $300 million in business and more than 200 new jobs to New Jersey, Celularity and MuseCell Innovations are making it clear that our state is open for business. I first visited Celularity in 2022, and its trajectory from a homegrown startup here in New Jersey to a thriving public company is everything that drives my optimism about the potential of the New Jersey innovation economy. Advanced biomanufacturing continues to grow as a strong pillar of our economy, and investments like this are critical to driving job growth across our state. New Jersey is the medicine chest of the world, and my administration will keep working to make our government more accountable for businesses and position our state as the global leader in life sciences,” said New Jersey Governor Mikie Sherrill.

A Source-Flexible Platform Defined by the Dezawa Method

Professor Mari Dezawa, M.D., Ph.D., discovered Muse cells as a naturally occurring, stress enduring cell population. Dezawa MuseCell biology and investigational applications have since been described in more than 170 peer-reviewed publications and evaluated in multiple human clinical studies. The Dezawa MuseCell platform combines qualified starting materials with the licensed Dezawa Method and MCI product specifications addressing identity, purity, viability, potency, traceability and lot release. This common manufacturing and quality framework is intended to preserve defined DMC identity across qualified bone marrow, adipose and perinatal sources while allowing source-specific biological characteristics to be evaluated and controlled.

“Celularity brings the infrastructure and technical depth required to establish U.S. manufacturing across qualified bone marrow, adipose and perinatal sources,” said Dominik Duscher, M.D., Ph.D., Chief Executive Officer and President of MuseCell Innovations. “The central scientific and quality principle is that Dezawa MuseCell identity is defined by manufacture under the licensed Dezawa Method and conformance to MCI’s product specifications—not by the anatomical source alone. That distinction allows the platform to expand without abandoning the methodology and standards that define the DMC phenomenon.”

“I discovered Dezawa MuseCells as a naturally occurring, stress-enduring cell population,” said Professor Mari Dezawa, M.D., Ph.D., Chair of MCI’s Scientific Advisory Board. “As manufacturing expands across qualified tissues, reproducibility depends on preserving the Dezawa Method and the defining product characteristics on which the platform was developed. Celularity provides an important opportunity to scale that approach in the United States, adding another home to the DMC global production.”

Quality, Traceability and Manufacturing Control

MCI’s platform is designed to document source qualification, manufacturing authorization, lot level testing and chain of custody through authorized distributors. The collaboration is intended to expand MCI’s U.S. manufacturing network while preserving product-specific quality controls and the distinction between MCI-authenticated DMC products and unverified SSEA-3-positive preparations manufactured outside the licensed Dezawa Method and MCI’s release framework.

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity leverages the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease. Celularity’s cellular therapy portfolio includes cenplacel-L, its placental-derived allogeneic cell therapy, and other investigational cellular therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose built facility supporting the development and manufacture of cellular therapies and advanced biomaterials.

For more information, please visit www.celularity.com.

About MuseCell Innovations

MuseCell Innovations® Pte. Ltd. (“MCI”), headquartered in Singapore, is the owner of the Dezawa MuseCell platform based on the discoveries of Professor Mari Dezawa, M.D., Ph.D. The platform encompasses Dezawa MuseCells, Dezawa MuseExosomes and Dezawa MuseSecretome and is defined by licensed manufacturing, MCI-controlled product specifications, lot-level testing and traceability. Muse cell biology and investigational applications have been described in more than 170 peer-reviewed publications and evaluated in multiple human clinical studies.

For more information, please visit www.musecellinnovations.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws, including statements regarding the collaboration between Celularity and MCI; the timing, execution and success of technology transfer, process development, manufacturing readiness activities, qualification, scale-up and product release; Celularity’s ability to establish manufacturing capability for DMCs from qualified bone marrow, adipose and perinatal sources; the ability of the licensed Dezawa Method and MCI product specifications to support reproducible manufacturing across source materials; the parties’ efforts to expand manufacturing to DMC-derived products; Celularity’s proprietary cellular medicine programs; and the parties’ plans and objectives in cellular medicine, regenerative medicine and longevity; and MCI’s estimate that its aggregate purchases from Celularity could exceed $300 million over the next five years.

Forward-looking statements are based on current expectations, estimates, assumptions and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include, among others, inability to complete technology transfer, qualify or validate a manufacturing process, achieve target yields, demonstrate comparability or release product; source-material and batch variability; unexpected technical or development challenges; safety, quality, regulatory, legal, intellectual-property, supply-chain, financing and commercial risks; changes in applicable laws or regulatory interpretations; and other risks described in Celularity’s filings with the U.S. Securities and Exchange Commission. The estimated value of potential purchases and statements regarding potential employment opportunities are based on current market conditions and assumptions regarding future demand, production requirements, product mix, pricing, successful manufacturing qualification, the scope and timing of any expansion of the collaboration, anticipated production volumes, staffing requirements and the parties’ continued collaboration. These statements do not constitute binding purchase or employment commitments, and there can be no assurance that MCI will make purchases in the amounts or within the time periods anticipated, or at all beyond its existing contractual commitments, or that any particular number of employment opportunities will be created, supported or retained, within any anticipated timeframe or at all. Neither cenplacel-L nor any MCI product described in this release has been approved or licensed by the U.S. Food and Drug Administration for any indication or use. Except as required by law, Celularity undertakes no obligation to update or revise any forward-looking statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260827982573/en/

Media and Investor Contact

Celularity Inc.

info@celularity.com

MuseCell Innovations

mci@jacktaylorpr.com

info@musecellinnovations.com

Source: MuseCell Innovations

Source link

CHIPS Act R&D Stalls as Manufacturing Surges Ahead

On 6 August, the U.S. Government Accountability Office (GAO) released a report on the state of the 2022 CHIPS and Science Act, a bipartisan federal law passed under the Biden Administration to boost U.S. semiconductor manufacturing and R&D. While manufacturing projects funded by the act are making notable progress, the money earmarked for R&D remains mostly unused, and the Department of Commerce, which administers the funds, has not published a plan for meeting the requirements of the law, according to the report. GAO says this lapse could put the U.S. at risk of missing out on the opportunity to advance semiconductor tech.

The industry experts we spoke with agree with GAO’s assessment. That includes Donna Dubinsky, serial entrepreneur and former Commerce Department official.

“We need to be the leader in manufacturing as well as in research, both advanced manufacturing technology and advanced designs, and Congress apportioned money to do it,” she says. Dubinsky was a trustee of Natcast, the public-private research consortium tasked with administering the National Semiconductor Technology Center (NSTC), the CHIPS Act’s R&D component, until August 2025 when Commerce cancelled its $7.4-billion contract in favor of operating NSTC itself.

The April 2026 charter Commerce wrote for the NSTC “does not mention the strategy or contain sufficient detail to demonstrate plans for the NSTC to align with” the National Strategy on Microelectronics Research, a requirement of the CHIPS Act, GAO wrote. Commerce has also failed to involve the private sector in establishing its investment fund, another requirement of the Act. Commerce did not respond to a request for an update on its plans for meeting the national strategy and other CHIPS Act R&D requirements.

Instead of carrying out the original goals of the CHIPS Act, Dubinsky says, “we are choosing to not invest in future semiconductor technology leadership in the U.S, and I don’t understand that choice…Now it’s going to be in Belgium. It’s going to be in Tokyo. It’s going to be in Korea. It’s not going to be in the U.S.”

What is working in the United States, according to the GAO report, is the disbursement of manufacturing incentives.

CHIPS manufacturing incentives are working

Bars show the number of CHIPS Act manufacturing incentive award projects anticipated to complete in a given year. The line shows the running percentage of total projects anticipated to complete by the end of that year. Source: U.S. Government Accountability Office

The GAO report shows that CHIPS Act-funded manufacturing programs are progressing. As of April 2026, 24 out of the 144 milestones across 49 projects had been completed, and the funding associated with them had been disbursed. Since April, Commerce has announced seven additional projects (five for USA Rare Earth, one each for Bosch and Powerex).

GlobalWafers, a Taiwan-headquartered silicon wafer company, is building wafer production facilities in Texas and Missouri with CHIPS Act direct grant support. They have had no problems receiving their milestone-based incentives so far, says Brent Omdahl, senior vice president of government affairs. They completed phase one of their Texas facility last year, receiving the promised $200 million shortly afterward.

“Obviously everybody in industry got perhaps a little anxious when President Trump, at the beginning of the administration, said he didn’t like the direct grant program,” Omdahl says. But he says he hasn’t heard of the government coming back to awardees to ask for equity positions, something industry watchers were concerned about. If anything, the Trump Administration’s changes to the CHIPS direct grant program have made the company’s work run more smoothly, he says.

According to the GAO report, a majority of CHIPS Act manufacturing projects will be complete by 2028, with all expected to finish by 2033.

R&D is floundering

The GAO reports that the Department of Commerce has disbursed only about $506.8 million of $11 billion appropriated for R&D. Commerce has also made new awards totaling $900 million outside the original CHIPS Act R&D framework.Source: U.S. Government Accountability Office

Since the arrival of the new administration, Commerce has cancelled $7.8 billion of the $11 billion appropriated for R&D under the CHIPS Act. Most of that was intended to go to Natcast to operate NSTC.

Commerce has funded two components of the R&D arm of the CHIPS Act, GAO reports: about $347 million for metrology research conducted by the National Institute of Standards and Technology and less than $5 million on the Act’s Small Business Innovation Research component.

Outside the cancelled NSTC framework, Commerce has since awarded $900 million to xLight, Sandbox AQ, and I-Pulse, and promised an additional $2 billion in preliminary awards for quantum computing it intends to take from CHIPS Act R&D funds, the GAO reports.

Unlike awards under the NSTC framework, these awards required equity from the companies in exchange for the government funds. “They’re using these funds for investment in equity, when these are companies that have access to the capital markets,” Dubinsky says, “If private capital is serving a sector well, then there’s no need for the government to play a role. The whole idea of this program was to provide leverage that would enable substantially more private sector investment.”

VJ Sahi, a partner and vice president at government funding consultancy Clark Street Associates, notes that “there were no significant developmental awards in flight” within the NSTC, so its cancellation may not have harmed valuable research or development so much as delayed it. “The trade-off has been a delay…but it has also provided more available capital [which is positive] if they can now move to deploy those R&D dollars on a reasonable schedule.”

From Your Site Articles

Related Articles Around the Web

Source link

2 ETFs Play the Reshoring Boom

Traditionally speaking, when new threats of tariffs hit the headlines, it tends to be a bad thing for many investment approaches.

• While escalating tariffs could be a concern for the markets, a couple of different sectors may be more insulated than others.
• This includes sectors engaged in reshoring: the process in which a company moves its production or manufacturing back to its original country.
• Both the iShares U.S. Manufacturing ETF (MADE B) and the Amplify Lithium & Battery Technology ETF (BATT ) could offer compelling routes to take advantage of momentum in the reshoring space.

Granted, there are plenty of fair reasons why tariffs become a problem for the market. Not only do tariffs tend to ratchet up geopolitical tensions, but they can also cause the price of certain imported goods and raw materials to increase.

However, there are some sectors of the market that tend to be less exposed to the dangers of tariffs. This includes companies that benefit from reshoring—the act of moving a company’s manufacturing or production operations back to its original country.

Companies currently thoroughly engaged in the reshoring process could be at a distinct advantage as tariffs continue to escalate. After all, businesses with stronger domestic supply chains may require less international shipping, and thus can avoid some of these rising costs.

Notably, the United States has a number of reshoring incentives that benefit different sectors of the market. This includes the Chips & Science Act for semiconductors, and Inflation Reduction Act for clean energy. Additionally, the industrials sector is benefitting from different manufacturing companies engaging in reshoring.

See More: Take-Two Latest Earnings: Try These 2 ETFs Ahead of GTA 6

Since reshoring can benefit a few different sectors, advisors and investors have some different options for how they wish to capitalize on the trend. For instance, the iShares U.S. Manufacturing ETF (MADE B) could be a straightforward option.

MADE invests in companies based in the United States that are heavily engaged in the manufacturing industry. This approach can help investors capitalize on reshoring, while attaining targeted domestic manufacturing exposure. As of July 31, 2026, the fund is offering a year-to-date total return of 17.88%.

See More: Balance China’s Shifting Lithium Market With the BATT ETF

Another option is to take a look at the Amplify Lithium & Battery Technology ETF (BATT ). BATT invests in companies that derive significant revenue from the lithium battery industry, which is a natural beneficiary of clean energy.

Leaning into a fund like BATT can help investors and advisors capitalize on clean energy reshoring, while tapping into the broad need for battery storage and lithium batteries as a whole. The fund’s NAV is up 16.45% year-to-date, as of August 26, 2026.

BATT and MADE showcase how there are plenty of different approaches that can work for tackling the reshoring opportunity set. Whether one wants to lean into clean energy, manufacturing, or a different sector entirely, the flexibility of the ETF wrapper allows folks to ensure there are plenty of options at their disposal.

For more news, information, and analysis, visit the Thematic Investing Content Hub.

VettaFi LLC (“VettaFi”) is the index provider for BATT, for which it receives an index licensing fee. However, BATT is not issued, sponsored, endorsed, or sold by VettaFi, and VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of BATT.

Source link